anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients with GBM/AA receive WSD0922-FU PO on days 1 and 4 of cycle 0. Patients then receive WSD0922-FU PO BID on days 1-28 of subsequent cycles. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo MRI during screening and on study, as well as blood sample collection on study. Patients may undergo additional optional blood sample collection on study.
Stable, orally administrable poliomyelitis vaccines are prepared by depositing an aqueous suspension of live, attenuated poliomyelitis viruses on the surface of a solid, pharmaceutically acceptable carrier and drying the so-treated carrier.  The drying is preferably carried out under sterile conditions and at a temperature of 0 DEG to 37 DEG  C.; it may be accelerated by means of reduced pressure or a gas stream, e.g. an air stream.  Viruses specified are Sabin's Types I, II and III and a mixture of these three types.  The carrier may be sugar candy kernels or solid gelatine kernels.  The treated carrier can be provided with an enteric coating.  Specification 888,171 is referred to.
NEW MATERIAL:The compound of formula I [R is H, lower alkyl, phenyl, phenoxy(lower alkyl), benzoyl(lower alkyl), or phenyl(lower alkyl); the dotted part represents single or double bond] and its salt. EXAMPLE:4-(4-Benzyl-1-piperazinylcarbonyl)carbostyryl monohydrochloride hemihydrate. USE:A cardiac useful as a remedy of various cardiac diseases such as congestive failure, mitral incompetence, atrial fibrillation, atrial flutter, etc. PROCESS:The compound of formula I can be prepared e.g. by the amidebond formation reaction of the compound of formula II with the piperazine derivative of formula III. The amide-bond formation reaction can be carried out, e.g. by reacting the compound of formula II with an alkylhalocarboxylic acid to obtain a mixed acid anhydride, and reacting the anhydride with the compound of formula III.
FIELD: medicine, pharmacy. ^ SUBSTANCE: invention refers to the field of medicine and pharmacy. The pharmaceutical composition includes Dimephosphon (dimethyl-oxobutyl-phosphonyl-dimethylat), Calcium Carbonate and Magnesium Mycellat substance, excipients and water with the following component ratio, w/w%: Dimephosphon - 1.0-20.0, Calcium Carbonate and Magnesium Mycellat substance - 1.0-10.0, excipients - 6.0-18.0, water - the remaining w/w %. The composition has a significant specific pharmacological effect demonstrating nootropic activity, does not produce a significant general toxic effect with different doses and routes of administration in experimental animals, does not have irritating and sensibilizing effects. ^ EFFECT: composition is an effective and safe product and can be used for normalization of central nervous system neurometabolic and cerebroprotective properties, as well as brain mental and mnestic functions, including those in patients with diabetes mellitus. ^ 3 cl, 1 tbl, 1 dwg, 5 ex
Postmarketing data from this formulation of CREON have been available since 2009. The following adverse reactions have been identified during post approval use of this formulation of CREON. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Gastrointestinal disorders (including abdominal pain, diarrhea, flatulence, constipation and nausea), skin disorders (including pruritus, urticaria and rash), blurred vision, myalgia, muscle spasm, and asymptomatic elevations of liver enzymes have been reported with this formulation of CREON.

Delayed- and immediate-release pancreatic enzyme products with different formulations of the same active ingredient (pancrelipase) have been used for the treatment of patients with exocrine pancreatic insufficiency due to cystic fibrosis and other conditions, such as chronic pancreatitis. The long-term safety profile of these products has been described in the medical literature. The most serious adverse reactions included fibrosing colonopathy, distal intestinal obstruction syndrome (DIOS), recurrence of pre-existing carcinoma, and severe allergic reactions including anaphylaxis, asthma, hives, and pruritus.
Subjects were implanted with the HARMONI® Modular Intraocular Lens System (HMIOL). The eye with the higher corneal astigmatism (study eye) was assigned to Cohort 1 and received the HARMONI® Modular Intraocular Lens System with a toric optic. The fellow eye was assigned to Cohort 2 and received the HARMONI® Modular Intraocular Lens System with a non-toric optic during primary implantation, which was replaced with the appropriate optic power (toric or non-toric) during an intraoperative exchange (IOE) procedure. A total of 7 study visits were planned, including a preoperative visit, operative visits for each eye, and 4 follow-up visits at 1 day, 1 week, 1 month, and 3 months postoperative. The total duration of participation for each subject was up to 6 months, which included a Day -90 to Day -0 preoperative period.

Alcon Research, LLC, acquired ClarVista Medical in 2017. This study was designed and conducted by ClarVista Medical, Inc. The study results were collected, analyzed, and provided by ClarVista Medical, Inc. to Alcon Research, LLC.
The invention discloses a dietetic nursing formula, which is prepared from Pleomele terniflora (Roxb.) Merr, Caesalpinia sappan L., Chassalia curviflora Thw, and Polygala fallax Hemsl. by processing. The formula can be daily eaten or taken as tea, and is used for preventing and treating alzheimer disease. The invention also discloses applications of the dietetic nursing formula in preparing health foods and medicines for preventing and treating alzheimer disease. The dietetic nursing formula disclosed by the invention is good in curative effect, small in toxic and side effects, price in cheap, and suitable for being clinically widely popularized.
BACKGROUND: Several studies have shown that people with whiplash-associated disorder (WAD) may experience diverse symptoms, and social, activity and participation limitations. However, the symptom profile of WAD is still unclear. Therefore, this systematic review aimed to identify the symptoms, impairments, activity limitations, and participation restrictions of people with WAD to construct a symptom profile.
METHODS: The data search was performed using PubMed, Embase, PsycINFO, CINAHL, and Scopus databases. Full-text quantitative and qualitative studies reporting symptoms, impairments, activity and participation limitations, or environmental factors affecting them in people with WAD were included. The extracted data was synthesised using Joanna Briggs Institute's convergent integrated approach. The Critical Appraisal Skills Programme checklist was chosen to evaluate the quality of the studies.
RESULTS: Fifty-three studies involving 102 943 people with WAD met the inclusion criteria. Three key themes were identified to describe the symptom profile: 1) the prevalence of symptoms, impairments or limitations; 2) the severity of symptoms and the effect of symptoms on functioning, activity and participation; and 3) the effects of environmental factors on the symptom profile. Two-thirds of the symptoms, impairments and limitations identified from the studies related to problems in body functions, and one-third to difficulties executing activities or participating in life situations.
DISCUSSION: The literature describes a wide variety of symptoms in people with WAD. However, it does not adequately describe how these symptoms affect a patient's function, activity, or levels of participation. Considering the symptom profile after whiplash injury to be primarily neck-related may be misdirected.
Extract isolated from periwinkle (Catharanthus roseus) seeds comprises proteins, amino acids, organic acids and sugars and is obtd. by bioconversion. Also claimed are:(a) a process for producing the above extract which comprises grinding periwinkle seeds, pre-digesting the ground seeds with an amylase and/or cellulase, fermenting the prod. with microorganisms and filtering, and(b) a compsn. contg. periwinkle extract.
AIM: To identify the symptoms and relevant factors associated with acute adrenal insufficiency of early-onset Sheehan syndrome.
METHODS: We retrospectively reviewed the charts of 125 women admitted to our intensive care unit because of postpartum hemorrhage between January 2011 and December 2021. Three women developed acute adrenal insufficiency. We investigated the total blood loss, shock status, consciousness level upon arrival, and intensive care provided to the women. We also analyzed the symptoms and laboratory data that led to the diagnosis of acute adrenal insufficiency. Continuous variables were presented by median (minimum-maximum).
RESULTS: The medians and ranges of age, total blood loss, and shock index [heart rate/systolic blood pressure] on admission were 33.1 (17.2-45.3) years, 3351 (595-20 260) g, and 0.94 (0.55-2.94), respectively. Seven women were older than 40 years, 28 experienced >5000 g blood loss, 17 had shock index >1.5, 27 had impaired consciousness upon arrival, and 15 underwent hysterectomy. Women who developed acute adrenal insufficiency were <40 years old and had a bleeding volume of over 5000 g, impaired consciousness upon arrival, and had undergone hysterectomy. They had experienced lactation failure, presented with hyponatremia-related symptoms on postpartum days 8-9, experienced general malaise, headache, and impaired consciousness, and showed severe hyponatremia.
CONCLUSIONS: Massive postpartum hemorrhage over 5000 g, impaired consciousness upon arrival, and hysterectomy as a hemostatic measure were relevant factors associated with acute adrenal insufficiency of early-onset Sheehan syndrome. Hyponatremia-related symptoms occurring after lactation failure are indicative of the onset of acute adrenal insufficiency.
Although recent meta-analyses of the HIV prevention intervention literature have demonstrated that behavioral interventions reduce sexual risk-taking among men who have sex with men (MSM), interventions for not-in-treatment substance using MSM are lacking. Consequently, and based upon overwhelming evidence that substance use is a primary driver of HIV infection among urban MSM, public health authorities have identified the development of efficacious interventions for substance using MSM as a concern of the highest priority. The proposed study aims to test a new intervention based upon psychological empowerment theory that, in preliminary field tests, produced high levels of acceptability and participation, as well as large reductions in sexual risks and substance use, among a sample of ethnically-diverse, high risk, substance using, HIV+ and -negative MSM. The intervention to be tested is based upon a theory of MSM health risk behaviors that posits that urban gay "fast lane" subcultures present risk environments - including lack of integration with the larger society, normative hypersexuality and substance use, homophobia, sexual competitiveness, and an emphasis on entertainment and escapism - that become problematic for a sizable minority of MSM who live in them.

The proposed project responds directly to the calls by public health authorities for the development of efficacious risk reduction interventions for substance using MSM. South Florida consistently ranks in the top three MSAs nationwide in HIV and AIDS incidence and prevalence. South Florida is also a well-known migration point for MSM of extraordinarily diverse backgrounds with high rates of non-injection drug use. This setting provides an excellent context for testing an innovative intervention among high risk substance using MSM who are in need of HIV prevention services.
Participants in this arm will also undergo a focused echocardiogram every 24 hours. However, the results of these echocardiograms will not be available for clinical decision-making. Instead, participants will receive usual care by the healthcare team without daily hemodynamic parameters from a study echocardiogram.
A gene delivery vehicle having been provided with at least a tissue tropism for cells selected from the group of smooth muscle cells, endothelial cells, and/or liver cells. The tissue tropism is generally provided by a virus capsid, such as one comprising protein fragments from at least two different viruses, such as two different adenoviruses, including adenovirus of subgroup C or subgroup B (for example, adenovirus 16). The protein fragments can comprises a tissue tropism determining fragment of a fiber protein derived from a subgroup B adenovirus. Also, cells for producing such gene delivery vehicles and pharmaceutical compositions containing said gene delivery vehicles. Further, a method of delivering nucleic acid to cells such as smooth muscle cells and/or endothelial cells which involves administering to the cells an adenovirus capsid having proteins from at least two different adenoviruses and wherein at least a tissue tropism determining fragment of a fiber protein is derived from a subgroup B adenovirus. Particular construct are also disclosed.
OBJECTIVE: Minimal residual disease assessment of BCR-ABL messenger ribonucleic acid levels is crucial in Philadelphia chromosome-positive acute lymphoblastic leukemia for prognosis and treatment planning. However, accurately quantifying minor BCR-ABL transcripts, which comprise 70% of Philadelphia chromosome-positive acute lymphoblastic leukemia cases, lacks a national-approved method.
METHODS: We developed the "Otsuka" minor BCR-ABLmessenger ribonucleic acid assay kit with exceptional precision (0.00151%). Minor BCR-ABL messenger ribonucleic acid levels were analyzed in 175 adults, 36 children with acute lymphoblastic leukemia and 25 healthy individuals to evaluate the kit's performance.
RESULTS: The "Otsuka" kit showed high concordance with a commonly used chimeric gene screening method, indicating reliable detection of positive cases. Quantitative results demonstrated a robust correlation with both a laboratory-developed test and a diagnostic research product. The "Otsuka" kit performs comparably or even surpass to conventional products, providing valuable insights into Philadelphia chromosome-positive acute lymphoblastic leukemia pathology.
CONCLUSIONS: The 'Otsuka" minor BCR-ABL messenger ribonucleic acid assay kit exhibits excellent performance in quantifying minor BCR-ABL transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia patients. Our results align well with established screening methods and show a strong correlation with laboratory-developed tests and diagnostic research products. The "Otsuka" kit holds great promise as a valuable tool for understanding Philadelphia chromosome-positive acute lymphoblastic leukemia pathology and guiding effective treatment strategies.
Clear cell renal cell carcinoma (ccRCC) is one of the most aggressive malignancies in the urological system, known for its high immunogenicity. However, its pathogenesis remains unclear. This study utilized bioinformatics algorithms and in vitro experiments to investigate the role of KAT7 in ccRCC. The results indicate that KAT7 is significantly downregulated in ccRCC tissues and cell lines, which is linked to distant metastasis and unfavorable outcomes in ccRCC patients. Overexpression of KAT7 in vitro notably decreased the proliferation, migration, and invasion of renal cancer cells and inhibited Epithelial-Mesenchymal Transition (EMT). Additionally, Gene Set Enrichment Analysis (GSEA) demonstrated that KAT7-related gene functions are associated with cell cycle and ferroptosis transcription factors. Treatment with a KAT7 acetylation inhibitor in ccRCC cell lines reversed the S phase arrest caused by KAT7 overexpression. Similarly, ferroptosis inhibitors alleviated ferroptosis induced by overexpressed KAT7. In conclusion, the findings suggest that KAT7 acts as a tumor suppressor in ccRCC by modulating the cell cycle and ferroptosis sensitivity, underscoring its potential as a therapeutic target and prognostic biomarker for renal cell carcinoma patients.
Double-strand breaks (DSBs) in DNA are challenging to repair. Cells employ at least three DSB-repair mechanisms, with a preference for non-homologous end joining (NHEJ) over homologous recombination (HR) and microhomology-mediated end joining (MMEJ). While most eukaryotic DNA is transcribed into RNA, providing complementary genetic information, much remains unknown about the direct impact of RNA on DSB-repair outcomes and its role in DSB-repair via end joining. Here, we show that both sense and antisense-transcript RNAs impact DSB repair in a sequence-specific manner in wild-type human and yeast cells. Depending on its sequence complementarity with the broken DNA ends, a transcript RNA can promote repair of a DSB or a double-strand gap in its DNA gene via NHEJ or MMEJ, independently from DNA synthesis. The results demonstrate a role of transcript RNA in directing the way DSBs are repaired in DNA, suggesting that RNA may directly modulate genome stability and evolution.
Cerebral ischemia-reperfusion injury (CIRI) is the second leading cause of death worldwide, posing a huge risk to human life and health. Therefore, investigating the pathogenesis underlying CIRI and developing effective treatments are essential. Ferroptosis is an iron-dependent mode of cell death, which is caused by disorders in iron metabolism and lipid peroxidation. Previous studies demonstrated that ferroptosis is also a form of autophagic cell death, and nuclear receptor coactivator 4(NCOA4) mediated ferritinophagy was found to regulate ferroptosis by interfering with iron metabolism. Ferritinophagy and ferroptosis are important pathogenic mechanisms in CIRI. This review mainly summarizes the link and regulation between ferritinophagy and ferroptosis and further discusses their mechanisms in CIRI. In addition, the potential treatment methods targeting ferritinophagy and ferroptosis for CIRI are presented, providing new ideas for the prevention and treatment of clinical CIRI in the future.
Epithelial ovarian cancer (EOC) is often diagnosed in advanced stage with peritoneal dissemination. Recent studies indicate that aberrant accumulation of collagen fibers in tumor stroma has a variety of effects on tumor progression. We refer to remodeled fibrous stroma with altered expression of collagen molecules, increased stiffness, and highly oriented collagen fibers as tumor-associated fibrosis (TAF). TAF contributes to EOC cell invasion and metastasis in the intraperitoneal cavity. However, an understanding of molecular events involved is only just beginning to emerge. Further development in this field will lead to new strategies to treat EOC. In this review, we focus on the recent findings on how the TAF contributes to EOC malignancy. Furthermore, we will review the recent initiatives and future therapeutic strategies for targeting TAF in EOC.
An orally ingestible sustained relief analgesic dosage composition comprises ethyl-cellulose-encapsulated particles of acetylsalicylic acid wherein (a) the weight ratio of ethyl cellulose to acetyl - salicylic acid can vary from 1:22 to 1:50, (b) the acetylsalicylic acid particles before encapsulation are distributively arranged in regard to size so that substantially all are caught on a screen having 0.149 mm. openings, a major portion are caught on a screen having 0.250 mm. openings and substantially all will pass through a screen having 0.841 mm. openings, (c) the preponderance of acetylsalicylic acid particles before encapsulation have a shape such that the largest dimension of a particle is not more than twice the second dimension, (i.e. the dimension at right angles to both the largest and smallest dimensions), and not more than four times the smallest dimension, (i.e. the smallest dimension at right angles to the largest dimension), such acetylsalicyclic acid particles consisting essentially of compacted granules of crystalline acetylsalicylic acid.  The composition may be in the form of tablets or capsules containing conventional excipients.  The compositions may also contain phenacetin, sodium salicylate, caffeine, salicylamide, acetaminophen, scopolamine, phenylephrine hydrochloride, glyceryl guaiacolate, chlorpheniramine maleate, belladonna alkaloids, dextromethorphan hydrobromide, ephedrine hydrochloride or phenylpropanolamine hyrochloride.
PURPOSE: To provide a medicinal compsn. effective for treatment of the premalignant or precancerous lesion which retards the progression of the premalignant epithelial lesion, i.e., the precancerous lesion. CONSTITUTION: This medicinal compsn. contains 9-cis-retionic acid, its pharmaceutically permissible salt or its pharmaceutically permissible hydrolyzable ester and therapeutically inert and pharmaceutically permissible carrier. The examples of the premalignant or precancerous epithelial lesions or diseases including the tumor effectively treated by the 9-cis-retionic acid include, the actinitic hyperkeratosis of the mucous membranes of the mouth, the tongue, the throat and the larynx, arsenic hyperkeratosis, xeroderma pigmentosum, Bowen's disease, leukoplakia, metaplasia disease, heteroplasia disease, the precancerous disease of the tunica mucosa bronchiorum, the heteroplasma disease and heteroplasia disease of the uterine neck, vulva dystrophy, the precancerous change of the bladder, etc.  When the compd. is locally applied on the skin, the symptoms relating to photodamage are restored. When the compd. is orally or locally dosed, the sebaceous secretion is decreased and the diseases, such as acne, oily hair and oily scalp are suppressed.
This is the first randomized controlled study aiming to assess the potential use of focal microvibration for the management of chronic lumbosacral radicular pain which is the pain consequent to the compression of a spinal nerve root. Focal microvibration has been so far used to treat gait disorders and instability consequent to diseases such as Parkinson's disease, stroke, ataxia, multiple sclerosis with impressive results and no reported side effects. Our trial involves three arms: one arm treated with a device able to deliver focal microvibration, one arm treated with a sham device, and one arm treated with standard pharmacological therapy according to international guidelines. Patients with the active and with sham devices will attach them on their skin for 6 hours/day except on Thursday and Sunday: this application schedule with two days of treatment suspension has intended to avoid habituation to the sub-perception microvibration stimulation. The follow up will be 12 months and periodic visits will be performed after 7, 15 30, 45, 60, 90, 180, and 360 days of treatment. All the patients enrolled in the study will have access to rescue analgesic drugs such as paracetamol 1g and tramadol 100mg in case on excessive pain. Randomization will be performed by a computer-generated sequence. During the follow up visits, patients will be asked to fill questionnaires to explore and monitor pain intensity and pain interference in daily life: brief pain inventory (BPI) and Oswestry disability index (ODI)
For conservative treatment apply TENS for 10 minutes to administer a micro current therapy to participants. Than Stretching exercises ( Hamstrings and Quadriceps), Strengthening exercises (Quadriceps, Hamstring, Calf ), Balance exercises and Ice Therapy.